Skip to main content
AQSZF logo

Aequus Pharmaceuticals Inc. (AQSZF) Stock Price & Analysis

Aequus Pharmaceuticals Inc. (AQSZF) — price $0.0003 (0.00%), as of the Nov 18, 2026 trading session.

Educational signal · not a buy or sell recommendation · How to read this

$0.0003 $0.00 (0.00%)

Aequus Pharmaceuticals Inc. · AQSZF

Aequus Pharmaceuticals Inc. is a Canadian specialty pharmaceutical company focused on developing and commercializing drugs in neurology, ophthalmology, and transplantation. The company markets products like Vistitan for glaucoma and Evolve dry eye products, while also developing extended-release treatments for epilepsy and cannabinoid-based therapeutics.

Price as of Nov 18, 2026

Key Statistics

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • SXTC · China SXT Pharmaceuticals, Inc. · 19 /100
  • IMCC · IM Cannabis Corp. · 22 /100
  • YCBD · cbdMD, Inc. · 23 /100

See all scored stocks →

Price & valuation

As of
MeasureValue
Latest provided price$0.0003
Change on the day0.00%
Price / earnings (trailing)3.13
Shares traded on the day5.0K

Price & events

Other perspectives

Council score for Aequus Pharmaceuticals (AQSZF): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

3 lenses, 3 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Strong
Gross Margin Moderate

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Aequus Pharmaceuticals (AQSZF), and what does it report?

Short answer · as of

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Aequus Pharmaceuticals Inc. (AQSZF) is the company analyzed here. In Q3 FY2025 it reported revenue of C$251,754 and net income of C$370,483.

2 · Latest results

What do the latest results show for Aequus Pharmaceuticals (AQSZF)?

Short answer · as of

The most recent reported quarter, Q3 FY2025, carried revenue of C$251,754.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2025C$251,754C$370,483C$0.0028 (diluted)
Q2 FY2025C$218,220-C$163,909-C$0.0012 (diluted)
Q1 FY2025C$226,545-C$645,101-C$0.0049 (diluted)
Q4 FY2024C$221,949-C$217,811-C$0.0016 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Aequus Pharmaceuticals (AQSZF)?

Short answer · as of

The distress and quality screens read Piotroski F 3. Trailing ratios: ROE -2.9% · current ratio 0.03 · earnings yield 31.1% · free-cash-flow yield -7.1%.

Data-derived red flags

  • Negative return on equity (-2.9%) — the business is not currently generating profit on shareholder capital.
  • Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held AQSZF in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported AQSZF in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

Aequus Pharmaceuticals Stock: Key Questions Answered

These answers are editorial: 1 of these 1 answer is drawn from the AQSZF research dossier (written Mar 16, 2026 by gemini-2.0-flash). Figures in this section are not part of the source register.

What does Aequus Pharmaceuticals Inc. do?

Aequus Pharmaceuticals Inc. is a Canadian specialty pharmaceutical company that develops and commercializes drugs in the therapeutic areas of neurology, ophthalmology, and transplantation. The company markets products like Vistitan for glaucoma and Evolve dry eye products.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 10 figures on this page — 8 from Financial Modeling Prep (FMP) and 2 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.